Literature DB >> 24807915

Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?

Dominique Sighoko1, Juxin Liu1, Ningqi Hou1, Paul Gustafson1, Dezheng Huo2.   

Abstract

INTRODUCTION: Discordance in hormone receptor status has been observed between two breast tumors of the same patients; however, the degree of heterogeneity is debatable with regard to whether it reflects true biological difference or the limited accuracy of receptor assays.
METHODS: A Bayesian misclassification correction method was applied to data on hormone receptor status of two primary breast cancers from the Surveillance, Epidemiology, and End Results database between 1990 and 2010 and to data on primary breast cancer and paired recurrent/metastatic disease assembled from a meta-analysis of the literature published between 1979 and 2014.
RESULTS: The sensitivity and specificity of the estrogen receptor (ER) assay were estimated to be 0.971 and 0.920, respectively. After correcting for misclassification, the discordance in ER between two primary breast cancers was estimated to be 1.2% for synchronous ipsilateral pairs, 5.0% for synchronous contralateral pairs, 14.6% for metachronous ipsilateral pairs, and 25.0% for metachronous contralateral pairs. Technical misclassification accounted for 53%-83% of the ER discordance between synchronous primary cancers and 11%-25% of the ER discordance between metachronous cancers. The corrected discordance in ER between primary tumors and recurrent or metastatic lesions was 12.4%, and there were more positive-to-negative changes (10.1%) than negative-to-positive changes (2.3%). Similar patterns were observed for progesterone receptor (PR), although the overall discordance in PR was higher.
CONCLUSION: A considerable proportion of discordance in hormone receptor status can be attributed to misclassification in receptor assessment, although the accuracy of receptor assays was excellent. Biopsy of recurrent tumors for receptor retesting should be conducted after considering feasibility, cost, and previous ER/PR status. ©AlphaMed Press.

Entities:  

Keywords:  Breast neoplasms; Discordance; Estrogen receptor; Metastasis biopsy; Metastatic breast carcinoma; Second primary neoplasm

Mesh:

Substances:

Year:  2014        PMID: 24807915      PMCID: PMC4041672          DOI: 10.1634/theoncologist.2013-0427

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  57 in total

1.  Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays.

Authors:  A Rhodes; B Jasani; A J Balaton; D M Barnes; E Anderson; L G Bobrow; K D Miller
Journal:  Am J Clin Pathol       Date:  2001-01       Impact factor: 2.493

2.  Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists.

Authors:  Thomas Rüdiger; H Höfler; H-H Kreipe; H Nizze; U Pfeifer; H Stein; F E Dallenbach; H-P Fischer; M Mengel; R von Wasielewski; H K Müller-Hermelink
Journal:  Am J Surg Pathol       Date:  2002-07       Impact factor: 6.394

Review 3.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

4.  Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.

Authors:  Allison W Welsh; Christopher B Moeder; Sudha Kumar; Peter Gershkovich; Elaine T Alarid; Malini Harigopal; Bruce G Haffty; David L Rimm
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

Review 5.  Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

Authors:  D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

6.  Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems.

Authors:  A Rhodes; B Jasani; D M Barnes; L G Bobrow; K D Miller
Journal:  J Clin Pathol       Date:  2000-02       Impact factor: 3.411

7.  Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.

Authors:  Yasutomo Sekido; Shinobu Umemura; Susumu Takekoshi; Yasuhiro Suzuki; Yutaka Tokuda; Tomoo Tajima; R Yoshiyuki Osamura
Journal:  Int J Oncol       Date:  2003-06       Impact factor: 5.650

8.  Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.

Authors:  Neal S Goldstein; Monica Ferkowicz; Eva Odish; Anju Mani; Farnaz Hastah
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

9.  Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.

Authors:  Sandra M Swain; John W Wilson; Eleftherios P Mamounas; John Bryant; D Lawrence Wickerham; Bernard Fisher; Soon Paik; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2004-04-07       Impact factor: 13.506

10.  Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.

Authors:  Giuseppe Bogina; Laura Bortesi; Marcella Marconi; Marco Venturini; Gianluigi Lunardi; Francesca Coati; Alberto Massocco; Erminia Manfrin; Cristina Pegoraro; Giuseppe Zamboni
Journal:  Virchows Arch       Date:  2011-06-04       Impact factor: 4.064

View more
  16 in total

1.  Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?

Authors:  Brenda F Kurland; Steffi Oesterreich
Journal:  J Nucl Med       Date:  2018-06-14       Impact factor: 10.057

2.  Epigenetic variations in breast cancer progression to lymph node metastasis.

Authors:  Guillermo Urrutia; Sergio Laurito; Diego M Marzese; Francisco Gago; Javier Orozco; Olga Tello; Teresita Branham; Emanuel M Campoy; María Roqué
Journal:  Clin Exp Metastasis       Date:  2015-01-28       Impact factor: 5.150

Review 3.  Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.

Authors:  Jin Zhang; Qianying Wang; Qing Wang; Jiangran Cao; Jiafu Sun; Zhengmao Zhu
Journal:  Cell Mol Life Sci       Date:  2019-08-30       Impact factor: 9.261

4.  Breast-Conserving Surgery in Bilateral Breast Cancer.

Authors:  Julie A O'Brien; Alice Ho; G Paul Wright; Michelle Stempel; Sujata Patil; Kate Krause; Monica Morrow; Mary L Gemignani
Journal:  Ann Surg Oncol       Date:  2015-08-12       Impact factor: 5.344

5.  Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer.

Authors:  Weipeng Zhao; Linlin Sun; Guolei Dong; Xiaorui Wang; Yan Jia; Zhongsheng Tong
Journal:  Ther Adv Med Oncol       Date:  2021-05-06       Impact factor: 8.168

6.  Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics.

Authors:  Nicole K Yun; Jessica A Slostad; Ankur Naqib; Casey Frankenberger; Claudia B Perez; Ritu Ghai; Lydia Usha
Journal:  Oncologist       Date:  2021-09-12

Review 7.  Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.

Authors:  Brenda F Kurland; Jay R Wiggins; Amandine Coche; Charlotte Fontan; Yann Bouvet; Peter Webner; Chaitanya Divgi; Hannah M Linden
Journal:  Oncologist       Date:  2020-05-15       Impact factor: 5.837

Review 8.  Regulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factors.

Authors:  Yingfeng Zheng; Leigh C Murphy
Journal:  Nucl Recept Signal       Date:  2016-01-13

9.  Hepatic Lesions Detected after Mastectomy, in Breast Cancer Patients with Hepatitis Background May Need to Undergo Liver Biopsy to Rule Out Second Primary Hepatocellular Carcinoma.

Authors:  Qi-wen Chen; Hai-jin Li; Ya-nan Chen; Zhou-yu Ning; Song Gao; Ye-hua Shen; Zhi-qiang Meng; Sonya Vargulick; Bi-yun Wang; Hao Chen
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

10.  Analyzing historical trends in breast cancer biomarker expression: a feasibility study (1947-2009).

Authors:  Nancy Krieger; Laurel A Habel; Pamela D Waterman; Melina Shabani; Lis Ellison-Loschmann; Ninah S Achacoso; Luana Acton; Stuart J Schnitt
Journal:  NPJ Breast Cancer       Date:  2015-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.